Genmab A/S

LSE:0MGB Stock Report

Market Cap: DKK 92.1b

Genmab Valuation

Is 0MGB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0MGB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0MGB (DKK1459.25) is trading below our estimate of fair value (DKK8996.45)

Significantly Below Fair Value: 0MGB is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0MGB?

Key metric: As 0MGB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0MGB. This is calculated by dividing 0MGB's market cap by their current earnings.
What is 0MGB's PE Ratio?
PE Ratio19.6x
EarningsDKK 4.70b
Market CapDKK 92.09b

Price to Earnings Ratio vs Peers

How does 0MGB's PE Ratio compare to its peers?

The above table shows the PE ratio for 0MGB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average53.3x
GNS Genus
140.2x37.0%UK£1.1b
BVXP Bioventix
24.2xn/aUK£199.7m
HIK Hikma Pharmaceuticals
17.8x11.2%UK£4.0b
NBIX Neurocrine Biosciences
30.8x29.6%US$11.9b
0MGB Genmab
19.8x23.7%DKK 92.1b

Price-To-Earnings vs Peers: 0MGB is good value based on its Price-To-Earnings Ratio (19.8x) compared to the peer average (53.3x).

Price to Earnings Ratio vs Industry

How does 0MGB's PE Ratio compare vs other companies in the European Biotechs Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0MGB 19.6xIndustry Avg. 26.8xNo. of Companies5PE020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0MGB is good value based on its Price-To-Earnings Ratio (19.8x) compared to the European Biotechs industry average (26.8x).

Price to Earnings Ratio vs Fair Ratio

What is 0MGB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0MGB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19.6x
Fair PE Ratio32.2x

Price-To-Earnings vs Fair Ratio: 0MGB is good value based on its Price-To-Earnings Ratio (19.8x) compared to the estimated Fair Price-To-Earnings Ratio (32.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0MGB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 1,462.50
DKK 2,396.59
+63.9%
16.0%DKK 2,970.00DKK 1,600.00n/a17
Nov ’25DKK 1,547.00
DKK 2,431.94
+57.2%
15.4%DKK 2,970.00DKK 1,600.00n/a17
Oct ’25DKK 1,621.60
DKK 2,409.94
+48.6%
15.9%DKK 2,970.00DKK 1,600.00n/a17
Sep ’25DKK 1,873.50
DKK 2,409.94
+28.6%
15.9%DKK 2,970.00DKK 1,600.00n/a17
Aug ’25DKK 1,963.61
DKK 2,454.35
+25.0%
15.3%DKK 3,000.00DKK 1,600.00n/a17
Jul ’25DKK 1,738.60
DKK 2,464.00
+41.7%
15.7%DKK 3,000.00DKK 1,600.00n/a17
Jun ’25DKK 1,927.50
DKK 2,465.76
+27.9%
15.7%DKK 3,000.00DKK 1,600.00n/a17
May ’25DKK 1,970.00
DKK 2,462.59
+25.0%
15.6%DKK 3,000.00DKK 1,662.00n/a17
Apr ’25DKK 2,084.00
DKK 2,461.17
+18.1%
16.0%DKK 3,190.00DKK 1,662.00n/a18
Mar ’25DKK 1,950.63
DKK 2,449.22
+25.6%
16.3%DKK 3,190.00DKK 1,662.00n/a18
Feb ’25DKK 1,916.28
DKK 2,513.56
+31.2%
14.2%DKK 3,190.00DKK 1,765.00n/a18
Jan ’25DKK 2,142.10
DKK 2,637.33
+23.1%
13.1%DKK 3,190.00DKK 2,000.00n/a18
Dec ’24DKK 2,158.00
DKK 2,686.22
+24.5%
14.4%DKK 3,320.00DKK 2,000.00n/a18
Nov ’24DKK 2,012.90
DKK 2,827.28
+40.5%
14.8%DKK 3,430.00DKK 1,965.00DKK 1,547.0018
Oct ’24DKK 2,515.79
DKK 2,895.61
+15.1%
12.4%DKK 3,430.00DKK 1,965.00DKK 1,621.6018
Sep ’24DKK 2,642.57
DKK 2,876.20
+8.8%
13.6%DKK 3,430.00DKK 1,965.00DKK 1,873.5020
Aug ’24DKK 2,758.60
DKK 2,864.95
+3.9%
15.5%DKK 3,400.00DKK 1,625.00DKK 1,963.6120
Jul ’24DKK 2,580.00
DKK 2,837.84
+10.0%
15.7%DKK 3,400.00DKK 1,625.00DKK 1,738.6019
Jun ’24DKK 2,735.22
DKK 2,866.70
+4.8%
15.3%DKK 3,400.00DKK 1,625.00DKK 1,927.5020
May ’24DKK 2,771.05
DKK 2,903.67
+4.8%
15.7%DKK 3,505.00DKK 1,625.00DKK 1,970.0018
Apr ’24DKK 2,580.96
DKK 2,903.67
+12.5%
15.7%DKK 3,505.00DKK 1,625.00DKK 2,084.0018
Mar ’24DKK 2,603.86
DKK 2,965.00
+13.9%
13.3%DKK 3,600.00DKK 2,150.00DKK 1,950.6318
Feb ’24DKK 2,673.26
DKK 3,021.94
+13.0%
13.3%DKK 3,600.00DKK 2,150.00DKK 1,916.2818
Jan ’24DKK 2,970.00
DKK 3,039.58
+2.3%
12.6%DKK 3,565.00DKK 2,150.00DKK 2,142.1019
Dec ’23DKK 3,295.00
DKK 2,992.00
-9.2%
12.4%DKK 3,505.00DKK 2,150.00DKK 2,158.0019
Nov ’23DKK 2,900.00
DKK 2,805.90
-3.2%
11.5%DKK 3,270.00DKK 1,950.00DKK 2,012.9020

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$81.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$754.00

7D

-8.8%

1Y

-6.0%

hVIVO

UK£178.6m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.25

7D

-10.9%

1Y

39.6%

Dermapharm Holding

€1.9b

Manufactures and sells off-patent branded pharmaceutical products in Germany.

0A5J

€34.28

7D

7.4%

1Y

-14.7%